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Abstract 
The management of localized breast cancer has changed dramatically over the past three to four decades. Breast-
conserving therapy, which involved lumpectomy followed by adjuvant irradiation, is now widely considered the 
standard of care in women with early-stage breast cancer. Accelerated partial breast irradiation (APBI), which involves 
focal irradiation of the lumpectomy cavity over a short period of time, has developed over the past two decades as an 
alternative to whole breast irradiation (WBI). Multiple APBI modalities have been developed including brachytherapy, 
external beam irradiation, and intraoperative irradiation. These new techniques have provided early-stage breast can-
cer patients with shorter treatment duration and more focused irradiation, delivering very high biological doses to the 
region at a high risk of failures over a much shorter treatment course as compared with conventional radiotherapy. 
However, the advantages of APBI over conventional radiotherapy are controversial, including a higher risk of compli-
cations reported in retrospective literature and shorter follow-up duration in the intraoperative APBI trials. Neverthe-
less, APBI presents a valuable alternative to WBI for a selected population of women with early-stage breast cancer.
Keywords: Accelerated partial breast irradiation, Brachytherapy, Breast cancer
© 2016 Akhtari and Teh. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The management of localized breast cancer has changed 
dramatically over the past three to four decades. Mastec-
tomy, the initial management of this disease, has shifted 
increasingly towards breast-conserving therapies (BCT) 
after landmark trials such as the National Surgical Adju-
vant Breast and Bowel Project B-06 [1], Milan [2], and 
the European Organization for Research and Treatment 
of Cancer 10801 [3] showed that mastectomy was equiv-
alent to breast-conserving surgery (BCS) followed by 
postoperative irradiation. In these trials, the addition of 
whole breast irradiation (WBI) after BCS decreased the 
chance of ipsilateral breast tumor recurrence by 50% or 
more, indicating the need for radiotherapy to address any 
residual microscopic disease. However, WBI usually con-
sists of 5–6 weeks of daily irradiation, which can impose 
certain logistical, economical, and social barriers to care. 
In fact, in women who undergo BCS, the percentage of 
patients who undergo radiotherapy can vary from 12% to 
77% depending on their age, access to a radiation therapy 
center, and comorbidities [4]. Additionally, 68% of ipsilat-
eral breast tumor recurrences are within 3 cm from the 
primary tumor, emphasizing the need to focus around 
the area of the initial disease and raising the neces-
sity of irradiation on the whole breast of patients with 
early-stage breast cancer. This has led to development of 
techniques that shorten the courses of radiation to the 
immediate area surrounding the tumor bed. Due to the 
decreased number of irradiation fractions, shortened 
treatment duration, and decreased size of the irradiation 
field, this group of treatments is collectively named accel-
erated partial breast irradiation (APBI).
Brachytherapy in APBI
One of the most widely used APBI approaches is via 
brachytherapy (B-APBI), which involves placement of 
radioactive sources into the breast tissue to deliver high 
doses of radiation to a confined area. Here we discuss the 
different forms of B-APBI and the existing data justifying 
their safety and efficacy.
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Interstitial brachytherapy
Interstitial brachytherapy is the first technique developed 
and used to treat only a partial amount of breast tissue. 
Although the first published series of interstitial brachy-
therapy date back to 1920s, breast interstitial brachy-
therapy did not come into prominence until the 1970s 
[5]. At that time, BCT was being developed, and since no 
electron beam therapy was available, a boost was given to 
the vicinity of the tumor bed using low-dose-rate (LDR) 
interstitial brachytherapy. With the advent of high-energy 
linear accelerators, electron beam boosts for the most 
part supplanted interstitial brachytherapy. However, in 
the meantime, brachytherapy techniques also improved 
dramatically along with better dose homogeneity, result-
ing in improved overall cosmesis [6]. As the experience 
with interstitial brachytherapy for boost grew, several tri-
als were undertaken to evaluate its safety and efficacy as 
the sole modality of irradiation after BCS.
To date, numerous single-arm and some randomized 
studies have been conducted examining multi-catheter 
interstitial brachytherapy. The results of the most impor-
tant trials are summarized in Table  1 [7–14]. Most of 
these studies enrolled patients with early-stage breast 
cancer, T1 or T2, with some allowing up to three positive 
axillary lymph nodes (N1). All studies required negative 
surgical margins and the majority of the trials excluded 
women with lobular or ductal carcinoma in  situ (LCIS 
or DCIS) histology. Interstitial catheters were placed 
anywhere from 4 to 8  weeks after surgery using either 
a free-hand technique or a breast template with the 
placed surgical clips as a point of guidance. Some of the 
later studies used 3-dimensional planning. Consistent 
with the general trends in overall use of brachytherapy, 
a percentage of earlier patients were treated with LDR or 
pulsed-dose-rate (PDR) sources, but the majority of the 
more recent patients were treated using 192Iridium (192Ir) 
high-dose-rate (HDR) brachytherapy. In almost all of the 
studies, the tumor bed plus 2 cm (some 1–2 cm) was cov-
ered by the radiation. LDR doses ranged from 45 to 50 Gy 
and HDR from 30 to 36 Gy using twice daily (BID) frac-
tionation. As seen in Table 2 [15–17], with careful patient 
selection, ipsilateral breast tumor recurrence rates were 
very low except for that in the Guy’s Hospital trial by 
Fentiman et al. [13], which reported an ipsilateral breast 
tumor recurrence rate of 18%. The overall cosmesis scores 
were good to excellent for the majority of the patients 
with low rates of late complications. Given the promising 
results of these and earlier studies, APBI slowly became 
an acceptable option for a limited population of patients 
with early-stage breast cancer. Its widespread use was 
however limited by the complicated insertion technique 
of interstitial brachytherapy catheters.
Single‑ and multi‑lumen applicators
In 2002, the Food and Drug Administration (FDA) of 
the United States approved the MammoSite® (Hologic, 
Bedford, MA, USA) balloon applicator, the first of its 
kind that simplified catheter insertion and usage of APBI 
Table 1 Results of randomized and single-arm interstitial brachytherapy trials
BID twice daily, HDR high-dose-rate, LDR low-dose-rate, PDR pulsed-dose-rate
Reported trial Number of patients Treatment  
volume








Wazer et al. [7] 32 Excision cav- 
ity + 2 cm
192Ir, 3.4 Gy BID to 
34 Gy
33 3 8 with fat necrosis, 
11 with grade 3–4 
skin toxicity
Arthur et al. [8] 44 (31 HDR, 13 LDR) Lumpectomy cav-
ity + 2 cm
192Ir, HDR: 3.4 Gy 
BID to 24 Gy; LDR: 
50 cGy/h to 45 Gy
42 0 43% of LDR patients 
had radiation recall 
with adriamycin
Benitez et al. [9] 199 Lumpectomy 
bed + 1–2 cm
LDR 125I, 0.52 Gy/h 
to 50 Gy; HDR 192Ir, 
3.2-3.4 Gy BID to 
32–34 Gy
68.4 1.2 11% fat necrosis, 
90% good-excel-
lent cosmesis
Ott et al. [10–12] 274 Tumor bed + 2 cm 192Ir, PDR: at 0.6 Gy 
pulses to 50 Gy; 
HDR: 4 Gy BID to 
32 Gy
63 2.9 2.6% ≥ grade 3 tox-
icity, 90% good to 
excellent cosmesis
Fentiman et al. [13] 50 Tumor bed + 2 cm 137Cs, 4 fractions, 
4–6 h/day to 45 Gy
75.6 18 82% good to excel-
lent cosmesis
Polgár et al. [14] 45 Tumor bed + 1–2 cm HDR 192Ir, 7 frac-
tions of 4.33 or 
5.2 Gy in 4 days to 
30.3–36.4 Gy
133 8.9 77.8% with good to 
excellent cosmesis, 
2.2% with fat 
necrosis
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compared with the placement of catheters in intersti-
tial brachytherapy (Fig. 1a). Between 2002 and 2004, 97 
institutions participated in a registry trial, which was 
designed to collect data on the use of MammoSite®. 
Collectively named the American Society of Breast Sur-
geons (ASBS) Registry Trial, a total of 1449 patients with 
early-stage breast cancer were treated using 34  Gy in 
10 BID fractions. At a median follow-up of 60  months, 
only 2.6% of the patients developed an ipsilateral breast 
tumor recurrence, and 90.6% had good or excellent cos-
mesis score. The rates of complications were low with a 
reported 2.3% of fat necrosis and 13% of symptomatic 
seromas [18]. In a separate analysis, the rate of axillary 
failure in the same registry of patients was 0.79% with a 
5-year overall survival (OS) rate of 77.8% in patients with 
an axillary failure [19]. Additionally, 194 of the patients in 
the MammoSite® registry trial were treated with a diag-
nosis of DCIS. Long-term follow-up with a median of 
54.4 months showed only a 3.1% rate of ipsilateral breast 
tumor recurrence [20].
As MammoSite® became increasingly popular, some of 
its shortcomings also became apparent. Given its single-
lumen catheter, dosimetric shaping and conformation 
to the surrounding tissue can be challenging. This led 
Table 2 Patient selection criteria for accelerated partial breast irradiation (APBI)
LVSI lymphovascular space invasion, DCIS ductal carcinoma in situ, ASTRO American Society of Therapeutic Radiation Oncology, pNi pathologically positive node 
determined by immunohistochemistry with a size ≤ 0.2 mm, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, – not mentioned, ASBS American Society 
















 Cautionary 50–59 2.1–3.0 – Limited/focal Close (<2 mm) Clinically  
unifocal
≤3 cm – ILC
 Unsuitable <50 >3 ≥pN1 Extensive Positive Multifocal >3 cm Used –
ASBS [16] ≥45 ≤3 N0 – Negative – ≤3 cm – IDC or DCIS
ABS [17] ≥50 ≤3 N0 – – Unifocal – – IDC
Fig. 1 Single- and multi-lumen/multi-catheter applicators used in accelerated partial breast irradiation. a An inflated 4X6 MammoSite® (Hologic, 
Bedford, MA, USA) balloon. b An inflated 4–5 Contura® (SenoRx, Inc., Aliso Viejo, CA, USA) balloon. c An expanded SAVI® (Cianna Medical, Aliso Viejo, 
CA, USA) 8–1 balloon (top) and placed in plastic model (bottom)
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to the development of other multi-lumen balloon-based 
catheters, including MammoSite ML® (Hologic, Bedford, 
MA, USA) and Contura® (SenoRx, Inc., Aliso Viejo, CA, 
USA). As opposed to the original MammoSite® balloon, 
which included a single lumen surrounded by an inflata-
ble balloon, the Contura® balloon includes a central cath-
eter and four surrounding fixed struts (Fig.  1b). Several 
dosimetric studies quickly showed lower dose delivered 
to organs at risk (OARs) using multi-lumen applica-
tors than using single-lumen applicators. Cuttino et  al. 
[21] compared the dose to the skin and chest wall for 43 
patients treated with interstitial multicatheter technique, 
45 treated with Contura®, and 83 with MammoSite® and 
observed higher maximum skin and rib doses by Mam-
moSite® compared with those by the multi-lumen tech-
niques. In another study, Brown et al. [22] compared 33 
patients treated with Contura® with 33 patients treated 
with MammoSite®. Despite closer skin spacing, the 
Contura® technique showed lower median skin dose, 
lower rib dose, and equal or better planning target vol-
ume (PTV) coverage as compared with the MammoSite® 
technique. Clinical outcome data using MammoSite® 
have also been promising, with a single-institution series 
reporting an ipsilateral breast tumor recurrence rate of 
2%, no grade 3–4 toxicities, and good/excellent cosmetic 
outcome in 97% of 46 patients at a median follow-up of 
36 months [23].
To allow even more dosimetric flexibility, Strut 
Adjusted Volume Implant (SAVI®, Cianna Medical, Aliso 
Viejo, CA, USA) was developed which included a central 
catheter surrounded by 6, 8, or 10 peripheral catheters 
(Fig. 1c). Initial results using SAVI® have been excellent 
dosimetrically, with evaluation of 102 patients treated 
revealing target volume receiving 90% of prescribed 
dose (V90) of 95.9% and maximum median skin dose of 
75% of prescribed dose [24]. At a median follow-up of 
21  months, the ipsilateral breast tumor recurrence rate 
was 1%, and the rate of symptomatic seroma or fat necro-
sis was 1.9%, showing low rates of toxicity and recur-
rence in carefully selected patients consistent with other 
B-APBI data.
Technique and catheter placement
Since the use of multi-catheter interstitial brachytherapy 
has declined dramatically in the recent past and is only 
reserved to few specialized centers, this section will 
instead focus on placement of single- and multi-lumen 
applicators (MammoSite®, Contura®, and SAVI®). Ini-
tial techniques for insertion of the MammoSite® balloon 
required placement either at the time of lumpectomy 
(open-cavity technique) or as a separate procedure 
(closed-cavity technique) up to 10  weeks after opera-
tion. If placed postoperatively, the device can then be 
inserted either through the surgical scar or through a 
separate incision. Ultrasound guidance is frequently used 
to detect the seroma, which in most cases associates with 
the actual tumor bed and aligns the route of insertion 
along the longest axis diameter of the cavity. Some insti-
tutions obtain a computed tomography (CT) scan several 
days before insertion of the catheter to measure the size 
of the cavity and estimate the needed device size. After 
insertion, the balloon is then inflated with sterile saline 
to a diameter of 4.0–5.0 cm, and a small amount of radio-
graphic material is added for contrast enhancement. A 
CT scan is then obtained after placement of the balloon 
to evaluate the conformance of the balloon to the cavity 
and absence of air or fluid gaps. A ratio of air or fluid in 
the cavity to balloon surface of less than 10% is usually 
deemed acceptable, and a balloon-skin distance equal 
or greater than 5 mm is ideal. The lumpectomy cavity is 
then delineated and expanded by 1 cm to define the PTV. 
Each expansion and PTV should conform to the patient’s 
anatomy, stay 5  mm from the skin, and remain at the 
edge of the pectoralis muscles and ribs. The most com-
monly prescribed dose is 3.4 Gy BID to a total of 34 Gy. 
Although normal tissue constraints can vary from insti-
tution to institution, the maximum allowable skin dose is 
kept below 100% of the prescription. If the balloon-skin 
distance is 5–7  mm, up to 145% of the prescribed dose 
is also acceptable. Ideally, 95% of the PTV should receive 
95% of the prescribed dose, and V150 and V200 (vol-
umes of tissue receiving 150% and 200% prescribed dose) 
should be limited to 50 and 20 cc, respectively. It is rec-
ommended that conformance and balloon-skin distance 
be assessed daily before each treatment session. The 
placement and dosimetric constraints of the Contura® 
and SAVI® balloons follow a similar protocol.
External beam APBI
As B-APBI was slowly growing in popularity, its use 
was still limited to centers with brachytherapy expertise 
and access to LDR or HDR afterloaders. If the rationale 
for B-APBI holds true that in the majority of early-stage 
breast cancer patients the risk of recurrence is limited 
to the area surrounding the lumpectomy cavity, then 
the same should hold true for treatment using external 
beam. Nevertheless, external beam APBI (EB-APBI) is 
not a relatively new concept, and some of the earliest tri-
als using EB-APBI date back to as early as 1980s. Ribeiro 
et al. [25] randomized 708 patients who were treated at 
Christie Hospital between 1982 and 1987 to undergo 
WBI to 40  Gy in 15 fractions or tumor bed-only irra-
diation using electrons to 40–42.5 Gy in eight fractions. 
After a median follow-up of 5.4  years, the ipsilateral 
breast tumor recurrence rate was 15%–34% for patients 
who underwent limited field irradiation compared with 
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8%–14% for patients who underwent WBI depending on 
the pathology. They noted that even though limited field 
electron irradiation was feasible, the local recurrence rate 
was higher than that of patients who underwent WBI, 
and better patient selection and treatment techniques 
were needed to improve outcomes. In another similar 
study, Dodwell et al. [26] randomized patients to undergo 
WBI to 40 Gy in 15 fractions or APBI to 55 Gy in 20 frac-
tions using electrons. The study accrued only 174 out 
of expected 400 patients and closed early due to non-
accrual. Although this limited any definitive conclusions 
that can be drawn from this study, the differences in the 
rates of ipsilateral breast tumor recurrence (WBI 4% vs. 
APBI 12%), locoregional failure (WBI 24% vs. APBI 9%), 
distant metastases (WBI 27% vs. APBI 23%), or OS (WBI 
73% vs. APBI 70%) were not significant.
More recently, the most significant EB-APBI trial to 
date, named the Randomized Trial of Accelerated Par-
tial Breast Irradiation (RAPID), released its interim 
cosmesis and toxicity analysis, showing higher rates of 
adverse cosmesis and late radiation toxicity in the EB-
APBI group compared with the WBI group [27]. In this 
study, 2135 patients with invasive ductal carcinoma 
(IDC) or DCIS with tumor size  ≤3  cm, negative surgi-
cal margins, negative nodes determined by pathologic 
assessment, and older than 40  years were randomized 
to either WBI to 42.5 Gy in 16 fractions or 50 Gy in 25 
fractions or EB-APBI to 38.5  Gy in 10 BID fractions of 
3.85 Gy. In the WBI group, 21% of the patients received 
boost to the tumor bed, and none in the EB-APBI group. 
After a median follow-up of 3 years, the EB-APBI group 
showed worse cosmetic outcome assessed either by trial 
nurse (33% vs. 13% in the WBI group) or by patient self-
assessment (32 vs. 21 % in the WBI group). The rates of 
grade 1–2 toxicity were higher in the EB-APBI group 
than in the WBI group. Although other non-randomized 
single- and multi-institution experiences from William 
Beaumont [28], RTOG 0319 [29], and Rocky Mountain 
Cancer Center [30] have shown good local control and 
cosmetic outcome, the results of the RAPID trial [27] 
have added to previous experiences from Tufts University 
[31] and University of Michigan [32] that had called into 
question the unacceptable rates of cosmesis and toxicity 
using EB-APBI. Therefore, at this point we do not recom-
mend using EB-APBI outside of the settings of a clinical 
protocol.
Intraoperative APBI
Intraoperative APBI (IO-APBI) has been a new and 
exciting development in APBI. The two most exten-
sively studied devices capable of delivering IO-APBI 
are the Intrabeam® device (Oberkochen, Germany) and 
the Novac7® device (Hitesys, Latina, Italy). Intrabeam® 
produces low-energy photons up to 50 kV using spheri-
cal applicators of varying sizes with intraoperative treat-
ment duration of approximately 30  min. In the recently 
updated targeted radiation therapy trial (TARGIT-A), 
an international cohort of participants enrolled 3451 
patients who were randomized to either conventional 
WBI per each center’s protocols or IO-APBI using Intra-
beam®, with a single 20  Gy fraction immediately after 
lumpectomy prescribed to the surface of the applica-
tor (about 5–7 Gy at 1 cm) [33]. If the patients had pre-
defined adverse pathologic features including LCIS, 
lymphovascular space invasion, positive nodal status, 
or other parameters defined at each center, postopera-
tive WBI was added, and the IO-APBI was counted as 
the boost. With a primary endpoint of local recurrence, 
the non-inferiority of IO-APBI was set at a 2.5% abso-
lute difference in local recurrence. At a median follow-up 
of 2  years and 5  months, the IO-APBI group showed a 
local recurrence rate of 3.3% vs. 1.3% in the WBI group 
(P = 0.04), meeting the non-inferiority criteria. Addition-
ally, the rates of OS or distant metastases were not sig-
nificantly different, and the IO-APBI group also showed 
low rates of grade 3–4 skin toxicity.
The Novac7® device has been evaluated in the Milan 
Electron IntraOperative Trial (ELIOT) study [34]. The 
device is a mobile accelerator capable of generating dif-
ferent electron energies ranging from 4 to 12 MeV. In this 
trial, 1305 patients were randomized either to conven-
tional WBI or to receive a single fraction of intraopera-
tive electrons to a dose of 21 Gy prescribed to the tumor 
bed. The target was surgically constructed, and the tho-
racic shielding was placed underneath the target. The 
total delivery duration was 30–40 min. Inclusion criteria 
included age >48 years and tumor diameter ≤2.5 cm in 
women who were eligible for BCS. After a median follow-
up of 5.8 years, 35 patients in the IO-APBI group and 4 
in the WBI group experienced ipsilateral breast tumor 
recurrence (P  <  0.0001), equaling 5-year event rates 
of 4.4% vs. 0.4%. The OS rate was similar between the 
two groups and the rate of skin adverse effects was sig-
nificantly lower in the IO-APBI group than in the WBI 
group (P = 0.0002).
Although the above IO-APBI trials show some promis-
ing early results, the follow-up for both trials is relatively 
short especially given that breast cancer can recur many 
years later. Other logistical issues also exist such as lim-
ited knowledge of tumor pathology at the time of the sur-
gery and high local recurrence rates seen in the ELIOT 
study. Additionally, the patients in these trials were 
highly selected, and it is unclear if IO-APBI can be con-
sidered a therapeutic option in any other group of early-
stage breast cancer patients. Nevertheless, these studies 
have paved the way for future investigations into the use 
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of IO-APBI. Given that it is extremely convenient for the 
patients and delivered in a single fraction at the time of 
the surgery, IO-APBI could be a reasonable option for a 
small subpopulation of early-stage breast cancer patients.
Selection criteria
To date, there have been no randomized trials compar-
ing WBI with B-APBI. As such, specific criteria that 
are deemed universally acceptable for patients who are 
appropriate for B-APBI are not known. In the early days 
of interstitial APBI, since the criteria had not yet been 
determined, the majority of patients treated were those 
with early-stage breast cancer. This trend continued to 
the era of single- and multi-lumen applicators. Through 
many years of cumulative experience, certain trends have 
started to emerge about which group of patients can 
safely undergo B-APBI. Therefore, professional societies, 
including the American Society of Therapeutic Radiation 
Oncology (ASTRO) [15], the American Society of Breast 
Surgeons (ASBS) [16], and the American Brachytherapy 
Society (ABS) [17], have put forward their own specific 
recommendations about which patients can be safely 
treated with APBI (Table  2). Of note, these recommen-
dations apply to all forms of APBI, including EB-APBI 
and IO-APBI, which will be discussed below. As can be 
seen from Table 2, ASTRO recommendations are divided 
into three categories labeled “suitable,” “cautionary,” and 
“unsuitable”. We recommend only treating patients under 
the suitable or those limited to one or two cautionary fea-
tures off of a randomized protocol.
It is also worthwhile mentioning that even though 
the above societies deemed the use of APBI acceptable 
in certain patient populations, a joint statement from 
three German oncology societies recommended refrain-
ing from APBI use outside of a prospective study [35]. 
They felt that there were not enough data available at the 
time to draw any conclusions about its safety and that it 
will also decrease the number of women who could be 
enrolled in ongoing prospective studies [35].
Controversies in APBI
In 2012, Smith et  al. [36] reported that based on their 
retrospective review of the surveillance, epidemiology, 
and end results (SEER)-Medicare database, women who 
underwent APBI between 2003 and 2007 had a higher 
rate of subsequent mastectomy than those who under-
went WBI (3.95% vs. 2.18%, P < 0.001). APBI treatment 
was also more frequently associated with higher rates of 
infectious and non-infectious postoperative complica-
tions, breast pain, fat necrosis, and rib fracture than WBI. 
The 5-year OS rate however did not differ between the 
two groups. In a follow-up report, Smith et al. [37] strati-
fied the same population of patients treated with APBI 
based on the ASTRO consensus guidelines into the suita-
ble, cautionary, and unsuitable groups. Overall, APBI did 
result in a significant reduction in the risk of mastectomy 
as compared with lumpectomy alone (2.8% vs. 4.7%). 
However, the risk reduction was not significant as com-
pared with WBI (2.8% vs. 1.3%). Stratification based on 
the ASTRO suitability criteria did not show a difference 
in the relative risk of mastectomy (P  =  0.84), although 
suitable patients overall had a low absolute risk of mas-
tectomy after APBI (1.6%).
It is important to keep in mind several limitations of 
the above studies. The limitations of retrospective studies 
are self-evident. Furthermore, mastectomy was used as a 
surrogate end-point since ipsilateral breast tumor recur-
rence itself is not listed in the SEER-Medicare database 
and a subsequent mastectomy can be due to a number of 
reasons unrelated to ipsilateral breast tumor recurrence. 
Additionally, the period studied (2003–2007) was imme-
diately after the approval of single- and multi-lumen 
applicators, with many investigators using the device for 
the first time so it is reasonable to expect relatively higher 
rates of complications such as infections and fat necrosis.
Another rising area of controversy in breast radia-
tion oncology involves the use of IO-APBI, to the point 
now that it has garnered national attention as reported 
on the Wall Street Journal [38]. Some of the controversy 
surrounds the rising rates of use of IO-APBI given its 
convenience in one intraoperative fraction and low cost 
burden to the health care system while questions regard-
ing its safety and efficacy still remain. Some of the issues 
raised in the ELIOT trial include a significantly higher 
relapse rate in the IO-APBI group compared with the 
WBI cohort, no accounting for adverse features on final 
pathology such as positive margin, higher rates of fat 
necrosis with IO-APBI, and final cosmesis analysis being 
performed on only a subset of the patients [39]. The 
TARGIT-A study has also faced multiple criticisms, such 
as the excess non-breast cancer deaths and an increased 
rate of secondary malignancy in the WBI group, both of 
which usually need much longer-term follow-up to ascer-
tain their significance [39].
Although the points raised in the above studies require 
consideration, the main questions about safety and effi-
cacy of APBI can only be answered in the ongoing rand-
omized clinical trials.
Future directions
APBI has now become a mainstay of treatment as part of 
the BCT algorithm. Even though it’s only a suitable option 
and should only be considered in patients with early-stage 
breast cancer based on the consensus statements discussed 
above, it provides a much faster and convenient alterna-
tive to WBI. However, definitive data from randomized 
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controlled trials, which are still ongoing, are needed. The 
most important of which, NSABP B-39/RTOG 0413 [40] is 
now closed to accrual. In this trial, WBI to 50–50.4 Gy in 
25–28 fractions with an optional 10–16 Gy boost is com-
pared with 34 Gy in 10 fractions delivered either via inter-
stitial brachytherapy, MammoSite®, MammoSite ML®, or 
SAVI® or with EB-APBI to a dose of 38.5  Gy in 10 frac-
tions delivered using 3-dimensional conformal radiation 
therapy. The selection criteria include patients with stage 
0, I, or II breast cancer resected by lumpectomy and with 
no more than three histologically positive nodes. The pri-
mary endpoint of the study is time to diagnosis of ipsilat-
eral breast tumor recurrence with secondary endpoints 
including OS and recurrence-free survival.
There are also other ongoing trials, including a study 
examining ultrashort-course APBI using Contura® 
(7  Gy  ×4 fractions) [41], the RAPID trial awaiting for 
final results, release of matured data of the TARGIT and 
ELIOT studies, and the randomized GEC-ESTRO trial 
[42]. With most of these trials approaching maturation, 
the exact role of APBI in the BCT paradigm will be fur-
ther solidified. Additionally, the appropriate group of 
patients who can benefit from different APBI modalities 
will be elucidated, allowing shorter treatment duration, 
better toxicity profiles, and considerable savings to the 
health care system [43].
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